What tests should I get after a GIST diagnosis

Tests After a GIST Diagnosis

After being diagnosed with a gastrointestinal stromal tumor (GIST), your oncology team will recommend several tests to understand your specific tumor and guide treatment decisions. Let me walk you through what's typically done and why.

Core Diagnostic Tests

Pathology Analysis of Your Tumor Tissue Your tumor sample will be examined under a microscope and tested for:

• KIT and PDGFRA mutations - These are genetic changes within the tumor cells (not inherited). About 95% of GISTs have a KIT mutation, and about 5% have a PDGFRA mutation. These mutations are crucial because they determine which targeted therapies will work best for your specific tumor.
• Mitotic rate - How quickly the tumor cells are dividing, which helps determine risk level
• Tumor size - Measured in centimeters

Imaging Studies

• CT scan of the abdomen and pelvis - Shows the tumor's location, size, and whether it has spread to other organs
• Chest CT - Checks for spread to the lungs (the most common site for GIST spread)

Risk Stratification

Based on your tumor size and mitotic rate, your doctor will classify your GIST as:

• Very low risk
• Low risk
• Intermediate risk
• High risk

This classification helps determine whether you need treatment and what type.

Additional Tests You May Need

Blood work:

• Complete blood count (CBC) - baseline before treatment
• Comprehensive metabolic panel - checks kidney and liver function
• Baseline blood tests before starting targeted therapy medications

Genetic Testing: If your tumor has an unusual mutation or doesn't have the typical KIT/PDGFRA mutations, additional molecular testing may be recommended.

Questions to Ask Your Oncology Team

1. "What specific mutations does my tumor have, and what does that mean for my treatment options?"
2. "What is my tumor's risk classification, and how does that affect my treatment plan?"
3. "Do I need any additional imaging or testing before we decide on treatment?"
4. "How often will I need follow-up imaging, and what will we be looking for?"
5. "Are there any clinical trials available for my specific mutation type?"

Important Context

According to NCCN (National Comprehensive Cancer Network) Guidelines for GIST, mutation status is one of the most important factors in determining treatment. Patients with KIT mutations typically respond well to tyrosine kinase inhibitors (targeted therapy drugs), while those with PDGFRA mutations may respond differently. This is why identifying your specific mutation is so critical.

Your oncologist will use all these test results together to create a personalized treatment plan. The combination of your tumor's characteristics, mutation status, and risk level guides whether you'll need surgery, targeted therapy, or both.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.